BioCryst Pharmaceuticals, Inc. (BCRX) Posts Q3 Loss of $0.32, Sales Miss Expectations
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $8.68 -0.23%
EPS Growth %: -43.8%
Financial Fact:
Loss from operations: -9.24M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: -43.8%
Financial Fact:
Loss from operations: -9.24M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) reported Q3 EPS of ($0.32), $0.06 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $5.25 million versus the consensus estimate of $6.84 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lennar Corp. (LEN) Misses Q3 EPS by 10c
- Forgent Power Solutions, Inc. (FPS) Tops Q2 EPS by 1c, Beats on Revenue; Offers FY27 Guidance
- Adobe Systems (ADBE) Tops Q3 EPS by 6c, Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
